Oncolytic adenoviruses - selective retargeting to tumor cells.
Virotherapy is an approach for the treatment of cancer, in which the replicating virus itself is the anticancer agent. Virotherapy exploits the lytic property of virus replication to kill tumor cells. As this approach relies on viral replication, the virus can self-amplify and spread in the tumor from an initial infection of only a few cells. The success of this approach is fundamentally based on the ability to deliver the replication-competent viral genome to target cells with a requisite level of efficiency. With virotherapy, while a number of transcriptional retargeting strategies have been utilized to restrict viral replication to tumor cells, this review will focus primarily on transductional retargeting strategies, whereby oncolytic viruses can be designed to selectively infect tumor cells. Using the adenoviral vector paradigm, there are three broad strategies useful for viral retargeting. One strategy uses heterologous retargeting ligands that are bispecific in that they bind both to the viral vector as well as to a cell surface target. A second strategy uses genetically modified viral vectors in which a cellular retargeting ligand is incorporated. A third strategy involves the construction of chimeric recombinant vectors, in which a capsid protein from one virus is exchanged for that of another. These transductional retargeting strategies have the potential for reducing deleterious side effects, and increasing the therapeutic index of virotherapeutic agents.
Mathis
J Michael
JM
Gene Therapy Program, Department of Cellular Biology and Anatomy, LSU Health Sciences Center, Shreveport, LA 71130, USA.
Stoff-Khalili
Mariam A
MA
Curiel
David T
DT
D000256:Adenoviridae / Q000235:genetics / Q000472:pathogenicity / Q000502:physiology*; D036022:Capsid Proteins; D004770:Enterovirus; D005822:Genetic Vectors; D008024:Ligands; D008099:Liver / Q000473:pathology / Q000821:virology; D009369:Neoplasms / Q000628:therapy / Q000821:virology; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000502:physiology*; D011956:Receptors, Cell Surface; D011991:Receptors, Virus / Q000502:physiology; D011994:Recombinant Proteins; D014158:Transcription, Genetic; D014161:Transduction, Genetic; D014779:Virus Replication
D036022:Capsid Proteins; D008024:Ligands; D011956:Receptors, Cell Surface; D011991:Receptors, Virus; D011994:Recombinant Proteins; C085301:adenovirus receptor